Multiple Sclerosis Discovery Forum

Inspiring Connections

Sort By: Most Recent Article / Most Recent Comments / Most Comments

New Findings | 23 Sep 2013

Oral Laquinimod May Reduce Destructive Pathology in RRMS

Laquinimod appears to reduce brain MRI findings of inflammatory destruction in relapsing-remitting multiple sclerosis

Laurie Barclay, M.D.

Treatment with oral laquinimod may reduce MRI evidence of destructive brain pathology in...

Clinical Research, Drug Development

New Findings | 16 Sep 2013

Corticosteroids Ineffective for Many With Relapsing MS

This study of nearly 4500 patients with MS concluded that although most felt corticosteroids helped them during relapses, a sizable percentage perceived no discernible effect or even harm

Steven Fox

Even though corticosteroid therapy, along with other therapies, is a cornerstone of managing relapsing-remitting multiple sclerosis...

Clinical Research

New Findings | 11 Sep 2013

First-Attack Multiple Sclerosis Targets Gray Matter

A new technique has identified changes in gray matter-related proteins in CSF that distinguished first-attack CIS from established relapsing-remitting MS and from controls

Daniel M. Keller, Ph.D.

Using a highly sensitive and precise proteomics technique, researchers have discovered...

Clinical Research, Laboratory Research

New Findings | 9 Sep 2013

Type 1 Diabetes Linked to Higher MS Risk Among Youth

Risk of comorbid MS was higher in youth with type 1 DM, but environmental factors may affect risk

Laurie Barclay, M.D.

Risk of comorbid multiple sclerosis was higher in children and adolescents with type 1 diabetes, but...

Clinical Research

New Findings | 9 Sep 2013

Sexual Dysfunction Fuels Mental Problems in MS Patients

Sexual dysfunction appears to have a significant impact on mental health in people with MS

Steven Fox

In people with multiple sclerosis, sexual dysfunction has a much more detrimental effect on...

Clinical Research

New Findings | 4 Sep 2013

Video Game Revs Up Brain Power

Targeted training boosts general working memory, attention

Carol Cruzan Morton

Even healthy aging brains can have a tough time concentrating in the middle of distractions and...

Clinical Research

New Findings | 26 Aug 2013

Natalizumab Emerges on Top in Network Meta-Analysis

There have been few head-to-head studies of disease-modifying drugs for MS. This study used a statistical technique called “network meta-analysis” to address that deficiency.

Steven Fox

How do the various drugs approved for treating relapsing multiple sclerosis compare with one another...

Clinical Research

New Findings | 22 Aug 2013

Phase 1 Trial of Stem Cells Begins in MS

The hope is that mesenchymal stem cell-derived neural progenitors will repair the damage wreaked by MS

Ricki Lewis, Ph.D.

Following investigational new drug approval by the U.S. Food and Drug Administration on August 24...

Clinical Research, Drug Development

New Findings | 19 Aug 2013

MS Cognitive Impairment Rates Lower Than Previously Reported

In a large MS group, cognitive impairment rates were unexpectedly low and few had severe impairment

Laurie Barclay, M.D.

In a large sample of persons with multiple sclerosis, rates of cognitive impairment were unexpectedly...

Clinical Research

New Findings | 12 Aug 2013

Plasma Osteopontin Levels: A New Marker for MS?

This study concluded that plasma osteopontin levels may be a marker for MS and neuromyelitis optica

Steven Fox

Elevated plasma osteopontin levels could prove to be a valuable biomarker not only for multiple sclerosis but also...

Clinical Research